Status:

TERMINATED

Phase II Open-Label Pilot Study of V3381 in Chronic Cough

Lead Sponsor:

Vernalis (R&D) Ltd

Collaborating Sponsors:

Manchester University NHS Foundation Trust

Conditions:

Cough

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

The investigators hypothesise that cough reflex hypersensitivity, demonstrated in chronic cough patients, is due to a phenomenon known as central sensitisation. Central sensitisation is a hyper-excita...

Eligibility Criteria

Inclusion

  • Male or female 18-75 years of age
  • Females must be of non child-bearing potential
  • Chronic Cough ( \> 8 weeks)
  • Normal Chest X-ray
  • Normal Lung Function
  • Idiopathic or treatment resistant cough-

Exclusion

  • Recent upper respiratory tract infection (\<4 weeks)
  • Pregnancy/breast-feeding
  • Current smokers or ex-smokers with \<6 months abstinence or cumulative history of \>10 pack years
  • Current treatment with ACE inhibitors.
  • Drug or alcohol abuse
  • Uncontrolled hypertension (i.e., \>140/90 mmHg despite adequate medical therapy).
  • Any cardiovascular condition that would be a contra-indication to the use of sympathomimetic amines (e.g. active angina).
  • Any clinically significant neurological disorder
  • Prior renal transplant, current renal dialysis.
  • Any clinically significant or unstable medical or psychiatric condition that would interfere with the patient's ability to participate in the study.
  • Increased risk of seizures.
  • Any malignancy in the past 2 years (with the exception of basal cell carcinoma).
  • Use of opioids, anticonvulsants, antidepressants (particularly MAO inhibitors).
  • Any clinically significant abnormal laboratory test result(s).
  • Serum creatinine laboratory value greater than 1.5 x upper limit of normal (ULN) reference range (after adjustment for age) or estimated creatinine clearance \<60 mL/min.
  • Total bilirubin greater than upper limit of normal reference range (with the exception of Gilbert's Syndrome) and/or alanine transaminase (ALT) \>1.5 times upper limit of normal reference ranges (after adjustment for age).

Key Trial Info

Start Date :

October 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2010

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT01401673

Start Date

October 1 2009

End Date

August 1 2010

Last Update

July 25 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

South Manchester University Hospital

Manchester, United Kingdom, M23 9LT

Phase II Open-Label Pilot Study of V3381 in Chronic Cough | DecenTrialz